COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED Revenue and Competitors

Location

$1.3M

Total Funding

Industry

Estimated Revenue & Valuation

  • COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED's total funding is $1.3M.

Employee Data

  • COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED has 55 Employees.(i)
  • COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED grew their employee count by -15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A193374%N/AN/A
#2
$25.6M84-6%N/AN/A
#3
$43.8M0N/A$28.5MN/A
Add Company

COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED is a company based out of 531 S Spring St, Burlington, NC, United States.

keywords:N/A

$1.3M

Total Funding

55

Number of Employees

N/A

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED's People

NameTitleEmail/Phone
1
Executive Director | Head Clinical Marketing | Marketing Strategy | BrandingReveal Email/Phone
2
Field Reimbursement ManagerReveal Email/Phone
3
Senior Medical DirectorReveal Email/Phone
4
IACUC Chair and ProcurementReveal Email/Phone
5
Sr. Pharmacovigilance OfficerReveal Email/Phone
6
President Clinical Operations and Commercial SolutionsReveal Email/Phone
7
Discovery PathologistReveal Email/Phone
8
Senior PathologistReveal Email/Phone
9
Study Coordinator III Level IReveal Email/Phone
10
Global Lead for Data & Technology: Strategy, Governance, Big DataReveal Email/Phone

COVANCE CLINICAL AND PERIAPPROVAL SERVICES LIMITED News

2011-12-23 - A clinical research organization wish list for Christmas (and new year)

A strategic partner: The biggest CROs such as, Quintiles, PPD, and Covance (NYSE:CVD) are increasingly moving toward strategic partnerships, making them a “preferred provider” of services. In these arrangements, a pharma will contract with a small number of CROs to handle the work. The deals may ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M556%N/A
#2
$7.2M55-24%N/A
#3
$7.5M554%N/A
#4
$12.1M552%N/A
#5
$12.1M558%N/A